Literature DB >> 12519080

A synthetic peptide from the heparin-binding domain III (repeats III4-5) of fibronectin promotes stress-fibre and focal-adhesion formation in melanoma cells.

José V Moyano1, Alfredo Maqueda, Juan P Albar, Angeles Garcia-Pardo.   

Abstract

Cell adhesion to fibronectin results in formation of actin stress fibres and focal adhesions. In fibroblasts, this response requires two co-operative signals provided by interactions of the RGD sequence with alpha5beta1 integrin and the heparin-binding domain II (Hep II) domain with syndecan-4. Within Hep II, this activity was mapped to repeat III13 and to the peptide FN-C/H-V(WQPPRARITGY, repeat III14). We previously described that the synthetic heparin-binding peptide/III5 (HBP/III5) (WTPPRAQITGYRLTVGLTRR, repeat III5) binds heparin and mediates cell adhesion via chondroitin sulphate proteoglycans. We have now studied whether HBP/III5 co-operates with alpha5beta1 and drives a full cytoskeletal response in melanoma cells. SKMEL-178 cells attached and spread on the RGD-containing FNIII7-FNIII10 (FNIII7-10) fragment, but did not form stress fibres or focal adhesions. Co-immobilization of HBP/III5 with FNIII7-10 or adding soluble HBP/III5 to cells prespread on FNIII7-10, effectively induced these structures. Cell transfection with dominant-negative N19RhoA, a member of the small GTPase family, abolished the HBP/III5 effect. Both chondroitinase and heparitinase diminished focal adhesions, indicating that both types of proteoglycans bound HBP/III5 in melanoma cells. We have mapped the active sequence of HBP/III5 to YRLTVGLTRR, which is a novel sequence in fibronectin with focal-adhesion-promoting activity. The last two arginine (R) residues of this sequence are required for activity, since their replacement by alanine completely abrogated the HBP/III5 cytoskeletal effect. Moreover, this sequence is also active in the context of large fibronectin fragments. Our results establish that the Hep III region provides co-operative signals to alpha5beta1 for the progression of the cytoskeletal response and that these include activation of RhoA.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12519080      PMCID: PMC1223291          DOI: 10.1042/BJ20021344

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  25 in total

Review 1.  Rho GTPases and their effector proteins.

Authors:  A L Bishop; A Hall
Journal:  Biochem J       Date:  2000-06-01       Impact factor: 3.857

Review 2.  Focal adhesions: a nexus for intracellular signaling and cytoskeletal dynamics.

Authors:  S K Sastry; K Burridge
Journal:  Exp Cell Res       Date:  2000-11-25       Impact factor: 3.905

Review 3.  Transmembrane crosstalk between the extracellular matrix--cytoskeleton crosstalk.

Authors:  B Geiger; A Bershadsky; R Pankov; K M Yamada
Journal:  Nat Rev Mol Cell Biol       Date:  2001-11       Impact factor: 94.444

Review 4.  Rho family proteins: coordinating cell responses.

Authors:  A J Ridley
Journal:  Trends Cell Biol       Date:  2001-12       Impact factor: 20.808

5.  Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack-1 and p130cas.

Authors:  K M Eisenmann; J B McCarthy; M A Simpson; P J Keely; J L Guan; K Tachibana; L Lim; E Manser; L T Furcht; J Iida
Journal:  Nat Cell Biol       Date:  1999-12       Impact factor: 28.824

6.  Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation.

Authors:  W Huang; R Chiquet-Ehrismann; J V Moyano; A Garcia-Pardo; G Orend
Journal:  Cancer Res       Date:  2001-12-01       Impact factor: 12.701

7.  Fibronectin regulates assembly of actin filaments and focal contacts in cultured cells via the heparin-binding site in repeat III13.

Authors:  L Bloom; K C Ingham; R O Hynes
Journal:  Mol Biol Cell       Date:  1999-05       Impact factor: 4.138

8.  Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells.

Authors:  T F Bumol; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1982-02       Impact factor: 11.205

9.  Fibronectin receptors of mononuclear phagocytes: binding characteristics and biochemical isolation.

Authors:  A Garcia-Pardo; O C Ferreira; J Valinsky; C Bianco
Journal:  Exp Cell Res       Date:  1989-04       Impact factor: 3.905

10.  Adhesion and cytoskeletal organisation of fibroblasts in response to fibronectin fragments.

Authors:  A Woods; J R Couchman; S Johansson; M Höök
Journal:  EMBO J       Date:  1986-04       Impact factor: 11.598

View more
  4 in total

1.  Enoxaparin Increases D6 Receptor Expression and Restores Cytoskeleton Organization in Trophoblast Cells from Preeclampsia.

Authors:  Chiara Tersigni; Giuseppe Maulucci; Roberta Castellani; Giada Bianchetti; Marianna Onori; Rita Franco; Greta Barbaro; Marco De Spirito; Antonio Lanzone; Giovanni Scambia; Nicoletta Di Simone
Journal:  Cells       Date:  2022-06-27       Impact factor: 7.666

2.  Alpha4beta1 integrin/ligand interaction inhibits alpha5beta1-induced stress fibers and focal adhesions via down-regulation of RhoA and induces melanoma cell migration.

Authors:  Jose V Moyano; Alfredo Maqueda; Benito Casanova; Angeles Garcia-Pardo
Journal:  Mol Biol Cell       Date:  2003-05-18       Impact factor: 4.138

3.  Mutations in FN1 cause glomerulopathy with fibronectin deposits.

Authors:  Federica Castelletti; Roberta Donadelli; Federica Banterla; Friedhelm Hildebrandt; Peter F Zipfel; Elena Bresin; Edgar Otto; Christine Skerka; Alessandra Renieri; Marta Todeschini; Jessica Caprioli; Rosa Maria Caruso; Rosangela Artuso; Giuseppe Remuzzi; Marina Noris
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-11       Impact factor: 11.205

4.  Heparin regulates B6FS cell motility through a FAK/actin cytoskeleton axis.

Authors:  Kallirroi Voudouri; Dragana Nikitovic; Aikaterini Berdiaki; Dionysios J Papachristou; John Tsiaoussis; Demetrios A Spandidos; Aristides M Tsatsakis; George N Tzanakakis
Journal:  Oncol Rep       Date:  2016-08-30       Impact factor: 3.906

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.